Last reviewed · How we verify
Livopan
Livopan, developed by the Federal University of Minas Gerais, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a competitive edge over pre-market competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Livopan |
|---|---|
| Also known as | equimolar mixture of nitrous oxide/oxygen |
| Sponsor | Federal University of Minas Gerais |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population (PHASE4)
- Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Livopan CI brief — competitive landscape report
- Livopan updates RSS · CI watch RSS
- Federal University of Minas Gerais portfolio CI